One Lot of Firvanq Recalled After Being Packaged with Wrong Diluent
September 8, 2021
Three Lots of Ruzurgi Recalled Due to Contamination
September 13, 2021
September 17, 2022 – Cabometyx® (cabozantinib) is now U.S. FDA approved for to treat patients at least 12 years old who are radioactive iodine-refractory (unresponsive to treatment) or ineligible and have locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy.
- First FDA-approved in 2012, Cabometyx is also indicated to treat renal cell carcinoma and hepatocellular carcinoma in patients who meet certain criteria.
- Recommended dosing under the DTC indication is 40mg once daily for pediatric patients who have a body surface area of less than 1.2m 2 and 60mg once daily for all other DTC patients.
- Manufactured by Exelixis, Inc., Cabometyx is an oral tablet that should be taken at least one hour before and two hours after eating.